• About
    • Our Story
    • Management
    • Board of Directors
  • Science
  • Pipeline
    • BH-30643
    • BH-30236
    • Posters and Presentations
  • Clinical Trials
  • News
  • Careers
  • Contact
  • Menu Menu

News

Keep up with the latest happenings at BlossomHill Therapeutics.

PRESS RELEASES | MEDIA

Press Releases

BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

January 5, 2026/in Press Releases/by David Anderson

January 5, 2026

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2026-01-05 07:02:032026-01-05 07:02:03BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

December 9, 2025/in Press Releases/by eallison

December 10, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-12-09 12:48:152025-12-09 15:30:48BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

November 3, 2025/in Press Releases/by David Anderson

November 3, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2025-11-03 08:15:482025-12-09 12:48:53BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2025/in Press Releases/by eallison

October 24, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-10-23 16:49:222025-10-29 08:20:27BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025/in Press Releases/by Steve Klass

October 14, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 Steve Klass /wp-content/uploads/BlossomHill-Logo_FullColor.svg Steve Klass2025-10-14 04:02:112025-10-14 08:14:42BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

August 22, 2025/in Press Releases/by eallison

August 22, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-08-22 14:06:152025-08-22 14:06:15BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

May 9, 2025/in Press Releases/by eallison

May 9, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-05-09 10:43:032025-05-09 10:43:03BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting

April 2, 2025/in Press Releases/by eallison

April 3, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-04-02 16:56:432025-04-03 05:04:22BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

January 22, 2025/in Press Releases/by eallison

January 22, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-01-22 10:50:142025-01-22 13:14:15BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President

January 3, 2025/in Press Releases/by eallison

January 6, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-01-03 12:01:552026-01-05 07:30:34BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President

BlossomHill Therapeutics Closes $100M Series B Financing

May 31, 2024/in Press Releases/by eallison

February 29, 2024

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:43:542024-06-09 20:49:06BlossomHill Therapeutics Closes $100M Series B Financing

BlossomHill Therapeutics Chief Executive Officer Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

May 31, 2024/in Press Releases/by eallison

February 14, 2024

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:43:412024-06-09 20:52:16BlossomHill Therapeutics Chief Executive Officer Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

BlossomHill Therapeutics Closes $71M Series A Financing

May 31, 2024/in Press Releases/by eallison

March 3, 2021

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:43:242024-06-09 20:53:31BlossomHill Therapeutics Closes $71M Series A Financing

Media

Blossomhill advancing EGFR, CLK inhibitors with series B extension

January 5, 2026/in Media/by eallison

December 31, 2025 | BioWorld

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2026-01-05 17:18:082026-01-05 17:18:08Blossomhill advancing EGFR, CLK inhibitors with series B extension

BlossomHill gets another $84M for macrocyclic approach to EGFR

January 5, 2026/in Media/by eallison

December 10, 2025 | Endpoints News

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2026-01-05 17:15:332026-01-05 17:16:10BlossomHill gets another $84M for macrocyclic approach to EGFR

This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

May 31, 2024/in Media/by eallison

February 29, 2024 | STAT News

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:41:412024-06-11 00:46:19This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

May 31, 2024/in Media/by eallison

February 29, 2024 | Endpoints News

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:41:292024-06-11 00:46:32BlossomHill raises $100M in bid to repeat founders’ cancer success at Turning Point

With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules

May 31, 2024/in Media/by eallison

February 29, 2024 | Fierce Biotech

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-31 14:41:032024-06-11 00:46:07With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules
© 2026 BlossomHill Therapeutics, Inc. | Terms of Service | Privacy Notice
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only